{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:16:10Z","timestamp":1794266170960,"version":"4.9.0"},"reference-count":432,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41409-025-02701-3","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:54:43Z","timestamp":1757433283000},"page":"1499-1525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"R.","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"A.","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"D. P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-3476","authenticated-orcid":false,"given":"J. A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"T.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"E.","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Averbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"A.","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Hazenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"K.","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-6178","authenticated-orcid":false,"given":"M.","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-1845","authenticated-orcid":false,"given":"H.","family":"Mekelenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-0935","authenticated-orcid":false,"given":"B.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-7160","authenticated-orcid":false,"given":"P.","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-5109","authenticated-orcid":false,"given":"A. M.","family":"Risitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"I.","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"F.","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"A.","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"2701_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41409-023-01924-6","volume":"58","author":"R Saccardi","year":"2023","unstructured":"Saccardi R, Putter H, Eikema DJ, Busto MP, McGrath E, Middelkoop B, et al. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transpl. 2023;58:659\u201366.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR2","unstructured":"Saccardi R, Rintala T, McGrath E, Snowden JA. JACIE Accreditation of HCT Programs. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, editors. The EBMT handbook: hematopoietic cell transplantation and cellular therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 5.PMID: 39437072 Free Books & Documents. Review."},{"key":"2701_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41409-019-0718-7","volume":"55","author":"JA Snowden","year":"2020","unstructured":"Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transpl. 2020;55:681\u201394.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, De La C\u00e1mara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651\u201364.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR5","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transplant [Internet]. 12 de febrero de 2025 [citado 13 de febrero de 2025]; Disponible en: https:\/\/www.nature.com\/articles\/s41409-025-02524-2."},{"key":"2701_CR6","doi-asserted-by":"publisher","first-page":"101556","DOI":"10.1016\/j.beha.2024.101556","volume":"37","author":"H Baldomero","year":"2024","unstructured":"Baldomero H, Neumann D, Hamad N, Atsuta Y, Sureda A, Iida M, et al. The role of registries in hematological disorders. Best Pract Res Clin Haematol. 2024;37:101556.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2701_CR7","doi-asserted-by":"crossref","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, De La Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339","DOI":"10.1038\/s41409-022-01691-w"},{"key":"2701_CR8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","volume":"14","author":"D Weisdorf","year":"2008","unstructured":"Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transpl. 2008;14:748\u201358.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR9","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/j.bbmt.2018.08.022","volume":"25","author":"D Weisdorf","year":"2019","unstructured":"Weisdorf D, Cooley S, Wang T, Trachtenberg E, Haagenson MD, Vierra-Green C, et al. KIR donor selection: feasibility in identifying better donors. Biol Blood Marrow Transpl. 2019;25:e28\u2013e32.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR10","doi-asserted-by":"publisher","first-page":"101557","DOI":"10.1016\/j.beha.2024.101557","volume":"37","author":"C Chabannon","year":"2024","unstructured":"Chabannon C, Ruggeri A, Montoto S, Van Biezen A, Van Der Werf S, Markslag A, et al. Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies. Best Pract Res Clin Haematol. 2024;37:101557.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2701_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med. 2024;390:687\u2013700.","journal-title":"N Engl J Med"},{"key":"2701_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco R, Alexander T, Del Papa N, Muller F, Saccardi R, Sanchez-Guijo F, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69:102476.","journal-title":"EClinicalMedicine"},{"key":"2701_CR13","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","volume":"32","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Cavazzana M, Frangoul H, Fuente JDL, Algeri M, Meisel R. Autologous gene therapy for hemoglobinopathies: from bench to patient\u2019s bedside. Mol Ther. 2024;32:1202\u201318. mayo de","journal-title":"Mol Ther"},{"key":"2701_CR14","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, Boreland W, Wolff D, Moiseev I, Schoemans H, et al. Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation. haematol [Internet]. 30 de mayo de 2024 [citado 4 de marzo de 2025]; Disponible en: https:\/\/haematologica.org\/article\/view\/haematol.2023.284810.","DOI":"10.3324\/haematol.2023.284810"},{"key":"2701_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 2024;30:338\u201341. febrero de","journal-title":"Nat Med"},{"key":"2701_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H. at al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2701_CR17","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/s41375-019-0439-3","volume":"33","author":"J Canaani","year":"2019","unstructured":"Canaani J, Labopin M, It\u00e4l\u00e4-Remes M, Blaise D, Soci\u00e9 G, Forcade E, et al. Prog- nostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944\u201352.","journal-title":"Leukemia"},{"key":"2701_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62\u201370.","journal-title":"Blood"},{"key":"2701_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/asheducation-2017.1.37","volume":"2017","author":"M Moarii","year":"2017","unstructured":"Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematol Am Soc Hematol Educ Program 2017;2017:37\u201344.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2701_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"2701_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329\u201336.","journal-title":"J Clin Oncol"},{"key":"2701_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00500-9","volume":"11","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Kim Y, Kang D, Kim HS, Lee JM, Kim M, et al. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J. 2021;11:109.","journal-title":"Blood Cancer J"},{"key":"2701_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood.2020005524","volume":"137","author":"L Fenwarth","year":"2021","unstructured":"Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis JH, Lesieur A, et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021;137:524\u201332.","journal-title":"Blood"},{"key":"2701_CR24","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allo-HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2701_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","volume":"120","author":"P Armand","year":"2012","unstructured":"Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905\u20131. Jul","journal-title":"Blood"},{"key":"2701_CR26","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2014.59.1339","volume":"33","author":"R Shouval","year":"2015","unstructured":"Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol. 2015;33:3144\u201351.","journal-title":"J Clin Oncol"},{"key":"2701_CR27","unstructured":"NCCN Guidelines Version 2.2025 Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN). Available at: https:\/\/www.nccn.org."},{"key":"2701_CR28","doi-asserted-by":"crossref","unstructured":"Versluis J, Cornelissen JJ, Craddock C, Sanz M\u00c1, Nagler A. AML in adults. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, editors. The EBMT handbook: hematopoietic cell transplantation and cellular therapies [Internet]. 8th edition. Cham (CH): Springer, 2024.","DOI":"10.1007\/978-3-031-44080-9_70"},{"key":"2701_CR29","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","volume":"2","author":"A Nagler","year":"2015","unstructured":"Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematol. 2015;2:e384\u201392.","journal-title":"Lancet Haematol"},{"key":"2701_CR30","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","volume":"100","author":"T Heinicke","year":"2021","unstructured":"Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021;100:2387\u201398. https:\/\/doi.org\/10.1007\/s00277-021-04565-1. Sep","journal-title":"Ann Hematol"},{"key":"2701_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41375-019-0527-4","volume":"34","author":"MH Gilleece","year":"2020","unstructured":"Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Soci\u00e9 G, Gedde-Dahl T, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2020;34:87\u201399.","journal-title":"Leukemia"},{"key":"2701_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood 2021;138:273\u201382. Jul","journal-title":"Blood"},{"key":"2701_CR33","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1200\/JCO.20.03502","volume":"39","author":"BE Shaw","year":"2021","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2021;39:1971\u201382. Jun","journal-title":"J Clin Oncol"},{"key":"2701_CR34","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348. de junio de","journal-title":"N Engl J Med"},{"key":"2701_CR35","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361. Apr","journal-title":"J Clin Oncol"},{"key":"2701_CR36","first-page":"483.e1","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial. Transpl Cell Ther. 2021;27:483.e1\u2013483.e6. Jun","journal-title":"Transpl Cell Ther"},{"key":"2701_CR37","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694\u2013706. Mar","journal-title":"Blood"},{"key":"2701_CR38","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/leu.2014.335","volume":"29","author":"J Schetelig","year":"2015","unstructured":"Schetelig J, Schaich M, Sch\u00e4fer-Eckart K, H\u00e4nel M, Aulitzky WE, Einsele H, et al. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia. 2015;29:1060\u20138.","journal-title":"Leukemia"},{"key":"2701_CR39","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.2019001425","volume":"134","author":"FG R\u00fccker","year":"2019","unstructured":"R\u00fccker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, et al. Measurable residual disease monitoring in acute myeloid leukemia with t (8;21)(q22;q22.1): results from the AML Study Group. Blood 2019;134:1608\u201318.","journal-title":"Blood"},{"key":"2701_CR40","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213\u201323.","journal-title":"Blood"},{"key":"2701_CR41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422\u201333.","journal-title":"N Engl J Med"},{"key":"2701_CR42","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69\u2013v82. Sep","journal-title":"Ann Oncol"},{"key":"2701_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139\u201349.","journal-title":"Haematologica"},{"key":"2701_CR44","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1002\/cncr.33522","volume":"127","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Koc Y, Angelucci E, Tischer J, Arat M, et al. Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:2507\u201314.","journal-title":"Cancer"},{"key":"2701_CR45","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 2024;143: 1903\u201330.","DOI":"10.1182\/blood.2023023568"},{"key":"2701_CR46","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189\u201397.","journal-title":"Blood"},{"key":"2701_CR47","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","volume":"111","author":"V Pullarkat","year":"2008","unstructured":"Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111:2563\u201372.","journal-title":"Blood"},{"key":"2701_CR48","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.3324\/haematol.2021.279046","volume":"106","author":"A Lazaryan","year":"2021","unstructured":"Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, et al. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021;106:2295\u20136.","journal-title":"Haematologica"},{"key":"2701_CR49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2019;54:798\u2013809.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR50","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","volume":"121","author":"V Gupta","year":"2013","unstructured":"Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121:339\u201350.","journal-title":"Blood"},{"key":"2701_CR51","first-page":"Cd008818","volume":"2011","author":"J Pidala","year":"2011","unstructured":"Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011;2011:Cd008818.","journal-title":"Cochrane Database Syst Rev"},{"key":"2701_CR52","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2015.179","volume":"50","author":"NC Gorin","year":"2015","unstructured":"Gorin NC, Giebel S, Labopin M, Savani BN, Mohty M, Nagler A. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transpl. 2015;50:1495\u2013502.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR53","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3324\/haematol.2014.116954","volume":"100","author":"E Brissot","year":"2015","unstructured":"Brissot E, Labopin M, Beckers MM, Soci\u00e9 G, Rambaldi A, Volin L, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100:392\u20139.","journal-title":"Haematologica"},{"key":"2701_CR54","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, et al. Combi- nation of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5:e618\u2013e27.","journal-title":"Lancet Haematol"},{"key":"2701_CR55","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib- blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2701_CR56","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","volume":"129","author":"N Jain","year":"2017","unstructured":"Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129:572\u201381.","journal-title":"Blood"},{"key":"2701_CR57","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41409-020-0849-x","volume":"55","author":"E Brissot","year":"2020","unstructured":"Brissot E, Labopin M, Russo D, Martin S, Schmid C, Glass B, et al. Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transpl. 2020;55:1763\u201372.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR58","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cncr.30604","volume":"123","author":"J Pavl\u016f","year":"2017","unstructured":"Pavl\u016f J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017;123:1965\u201370.","journal-title":"Cancer"},{"key":"2701_CR59","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisa- genlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"2701_CR60","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE- X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"2701_CR61","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330. de diciembre de","journal-title":"N Engl J Med"},{"key":"2701_CR62","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","volume":"33","author":"M Mohty","year":"2019","unstructured":"Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33:2767\u201378.","journal-title":"Leukemia"},{"key":"2701_CR63","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133:1652\u201363.","journal-title":"Blood"},{"key":"2701_CR64","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4:2325\u201338.","journal-title":"Blood Adv"},{"key":"2701_CR65","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3:3539\u201349.","journal-title":"Blood Adv"},{"key":"2701_CR66","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/bjh.17460","volume":"193","author":"B Dholaria","year":"2021","unstructured":"Dholaria B, Savani BN, Huang XJ, Nagler A, Perales MA, Mohty M. The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. Br J Haematol. 2021;193:1060\u201375.","journal-title":"Br J Haematol"},{"key":"2701_CR67","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331. https:\/\/doi.org\/10.1182\/blood-2017-08-798322. Apr","journal-title":"Blood"},{"key":"2701_CR68","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61:2665\u201373. Nov","journal-title":"Leuk Lymphoma"},{"key":"2701_CR69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J.IBFM Study Group;; Arend von Stackelberg; IntReALL Study Group; Adriana Balduzzi; I-BFM SCT Study Group; Selim Corbacioglu; EBMT Paediatric Diseases Working Party; Peter Bader et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295\u2013307. https:\/\/doi.org\/10.1200\/JCO.20.02529. Feb.","journal-title":"J Clin Oncol"},{"key":"2701_CR70","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","volume":"24","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M.Acute Leukemia Committee of the CIBMTR et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2018;24:726\u201333. Apr.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"S Eder","year":"2017","unstructured":"Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, et al. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: a matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:997\u20131003. Oct","journal-title":"Am J Hematol"},{"key":"2701_CR72","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114:5136\u201345.","journal-title":"Blood"},{"key":"2701_CR73","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863\u20139.","journal-title":"Blood"},{"key":"2701_CR74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","volume":"131","author":"A Petit","year":"2018","unstructured":"Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, et al. Onco- genetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131:289\u2013300.","journal-title":"Blood"},{"key":"2701_CR75","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","volume":"113","author":"V Asnafi","year":"2009","unstructured":"Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, et al. NOTCH1\/ FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113:3918\u201324.","journal-title":"Blood"},{"key":"2701_CR76","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384. Apr","journal-title":"Leukemia"},{"key":"2701_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2024;22:43\u201369. Feb","journal-title":"J Natl Compr Cancer Netw"},{"key":"2701_CR78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ajh.26764","volume":"98","author":"Y Chalandon","year":"2023","unstructured":"Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, et al. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol. 2023;98:112\u201321. Jan","journal-title":"Am J Hematol"},{"key":"2701_CR79","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341. Nov","journal-title":"Blood"},{"key":"2701_CR80","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350. Nov","journal-title":"Blood"},{"key":"2701_CR81","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127:2742\u201350. Jun","journal-title":"Blood"},{"key":"2701_CR82","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41375-024-02204-y","volume":"38","author":"A Brioli","year":"2024","unstructured":"Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, et al. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. 2024;38:1072\u201380. May","journal-title":"Leukemia"},{"key":"2701_CR83","first-page":"93.e1","volume":"30","author":"G Ort\u00ed","year":"2024","unstructured":"Ort\u00ed G, Gras L, Koster L, Kulagin A, Byrne J, Apperley JF, et al. Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: a comparative study from the chronic malignancies working party of the EBMT (CMWP-EBMT). Transpl Cell Ther. 2024;30:93.e1\u201393.e12. Jan","journal-title":"Transpl Cell Ther"},{"key":"2701_CR84","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/bjh.19448","volume":"204","author":"F Onida","year":"2024","unstructured":"Onida F, Gras L, Ge J, Koster L, Hamladji RM, Byrne J, et al. Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: a retrospective analysis from the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2024;204:2365\u201377. Jun","journal-title":"Br J Haematol"},{"key":"2701_CR85","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ajh.26833","volume":"98","author":"G Ort\u00ed","year":"2023","unstructured":"Ort\u00ed G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, et al. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023;98:628\u201338.","journal-title":"Am J Hematol"},{"key":"2701_CR86","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Holler E, Kobbe G, Bornh\u00e4user M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264\u201370.","journal-title":"Blood"},{"key":"2701_CR87","volume":"69","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Sirait T, Hern\u00e1ndez-Boluda JC, Czerw T, Hayden P, Yakoub-Agha I. European-wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Curr Res Transl Med. 2021;69:103267.","journal-title":"Curr Res Transl Med"},{"key":"2701_CR88","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u2013e74. Jan","journal-title":"Lancet Haematol"},{"key":"2701_CR89","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233\u201342.","journal-title":"Blood"},{"key":"2701_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Mauff K, Kroger N, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European Society for Blood and Marrow Transplantation (EBMT). Am J Hematol. 2021;96:69\u201379.","journal-title":"Am J Hematol"},{"key":"2701_CR91","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","volume":"35","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35:3551\u201360.","journal-title":"Leukemia"},{"key":"2701_CR92","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3324\/haematol.2018.200808","volume":"104","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 2019;104:929\u201336.","journal-title":"Haematologica"},{"key":"2701_CR93","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"2701_CR94","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388. 15 de marzo de","journal-title":"Blood"},{"key":"2701_CR95","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/leu.2015.37","volume":"29","author":"M Robin","year":"2015","unstructured":"Robin M, Porcher R, Ad\u00e8s L, Raffoux E, Michallet M, Fran\u00e7ois S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496\u2013501. julio de","journal-title":"Leukemia"},{"key":"2701_CR96","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol. 2021;39:3318\u201327. 20 de octubre de","journal-title":"J Clin Oncol"},{"key":"2701_CR97","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328\u201339. 20 de octubre de","journal-title":"J Clin Oncol"},{"key":"2701_CR98","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1200\/JCO.23.02175","volume":"42","author":"CA Tentori","year":"2024","unstructured":"Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, et al. Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes. J Clin Oncol. 2024;42:2873\u201386. 20 de agosto de","journal-title":"J Clin Oncol"},{"key":"2701_CR99","first-page":"71","volume":"29","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transpl Cell Ther. 2023;29:71\u201381. febrero de","journal-title":"Transpl Cell Ther"},{"key":"2701_CR100","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.2023022273","volume":"144","author":"C Scheid","year":"2024","unstructured":"Scheid C, Eikema DJ, van Gelder M, Salmenniemi U, Maertens J, Passweg J, et al. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms? Blood. 2024;144:445\u201356. de julio de","journal-title":"Blood"},{"key":"2701_CR101","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood.2023023476","volume":"143","author":"F Onida","year":"2024","unstructured":"Onida F, Gagelmann N, Chalandon Y, Kobbe G, Robin M, Symeonidis A, et al. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 2024;143:2227\u201344. May","journal-title":"Blood"},{"key":"2701_CR102","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201317.","journal-title":"Blood"},{"key":"2701_CR103","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. National cancer research institute chronic lymphocytic leukemia subgroup. chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326\u201337.","journal-title":"N Engl J Med"},{"key":"2701_CR104","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/ajh.26682","volume":"97","author":"JH Aronson","year":"2022","unstructured":"Aronson JH, Sk\u00e5nland SS, Roeker LE, Thompson MC, Mato AR. Approach to a patient with \u00abdouble refractory\u00bb chronic lymphocytic leukemia: \u00abdouble, double toil and trouble\u00bb (Shakespeare). Am J Hematol. 2022;97:S19\u2013S25.","journal-title":"Am J Hematol"},{"key":"2701_CR105","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"K Cwynarski","year":"2012","unstructured":"Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30:2211\u20137.","journal-title":"J Clin Oncol"},{"key":"2701_CR106","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","volume":"30","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462\u20139.","journal-title":"J Clin Oncol"},{"key":"2701_CR107","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2021-148039","volume":"138","author":"FL Locke","year":"2021","unstructured":"Locke FL, Jacobson C, Perales MA, Kersten MJ, Westin JR. Primary analysis of ZUMA\u20117: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard\u2011of\u2011care therapy in patients with relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2.","journal-title":"Blood"},{"key":"2701_CR108","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308. Jun","journal-title":"Lancet"},{"key":"2701_CR109","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315. May","journal-title":"Blood"},{"key":"2701_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01084-w","volume":"14","author":"M Shadman","year":"2024","unstructured":"Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, et al. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024;14:108. Jul","journal-title":"Blood Cancer J"},{"key":"2701_CR111","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145\u201354. Oct","journal-title":"Nat Med"},{"key":"2701_CR112","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447. DecEpub 2017 Dec 10","journal-title":"N Engl J Med"},{"key":"2701_CR113","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","volume":"15","author":"B Glass","year":"2014","unstructured":"Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15:757\u201366.","journal-title":"Lancet Oncol"},{"key":"2701_CR114","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJ van Kampen","year":"2011","unstructured":"van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29:1342\u20138.","journal-title":"J Clin Oncol"},{"key":"2701_CR115","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","volume":"174","author":"TS Fenske","year":"2016","unstructured":"Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174:235\u201348.","journal-title":"Br J Haematol"},{"key":"2701_CR116","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2017.03.031","volume":"23","author":"A Dodero","year":"2017","unstructured":"Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, et al. Allogeneic stem cell transplantation for relapsed\/refractory B cell lymphomas: results of a multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biol Blood Marrow Transpl. 2017;23:1102\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR117","first-page":"99","volume":"29","author":"S Fried","year":"2023","unstructured":"Fried S, Shouval R, Walji M, Flynn JR, Yerushalmi R, Shem-Tov N, et al. Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma. Transpl Cell Ther. 2023;29:99\u2013107. Feb","journal-title":"Transpl Cell Ther"},{"key":"2701_CR118","first-page":"750","volume":"29","author":"P Derigs","year":"2023","unstructured":"Derigs P, Bethge WA, Kr\u00e4mer I, Holtick U, von Tresckow B, Ayuk F.German Lymphoma Alliance and the German Registry for Stem Cell Transplantation et al. Long-term survivors after failure of chimeric antigen receptor t cell therapy for large b cell lymphoma: a role for allogeneic hematopoietic cell transplantation? a german lymphoma alliance and german registry for stem cell transplantation analysis. Transpl Cell Ther. 2023;29:750\u20136. Dec.","journal-title":"Transpl Cell Ther"},{"key":"2701_CR119","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3324\/haematol.2022.281242","volume":"108","author":"J Zurko","year":"2023","unstructured":"Zurko J, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023;108:98\u2013109. https:\/\/doi.org\/10.3324\/haematol.2022.281242. Jan","journal-title":"Haematologica"},{"key":"2701_CR120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","volume":"35","author":"AF Herrera","year":"2017","unstructured":"Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35:24\u201331.","journal-title":"J Clin Oncol"},{"key":"2701_CR121","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2020008750","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021;137:2307\u201320. https:\/\/doi.org\/10.1182\/blood.2020008750","journal-title":"Blood"},{"key":"2701_CR122","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, et al. Wholebrain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510\u2013e23.107.","journal-title":"Lancet Haematol"},{"key":"2701_CR123","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","volume":"127","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127:1642\u20139.","journal-title":"Blood"},{"key":"2701_CR124","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEFGOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37:823\u201333.","journal-title":"J Clin Oncol"},{"key":"2701_CR125","unstructured":"Illerhaus G, Ferreri A, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, et al. Consolidative HCT\u2010ASCT is superior to non\u2010myeloablative chemo-immunotherapy in newly\u2010diagnosed pcnsl \u2010 updated results of the randomized phase III Matrix\/IELSG43 trial. In Proceedings of the 17th ICML, abstract 015, Lugano, 13\u201317 June 2023."},{"key":"2701_CR126","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(23)00371-X","volume":"11","author":"E Schorb","year":"2024","unstructured":"Schorb E, et al. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024;11:e196\u2013e205. https:\/\/doi.org\/10.1016\/S2352-3026(23)00371-X","journal-title":"Lancet Haematol"},{"key":"2701_CR127","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","volume":"19","author":"C Soussain","year":"2001","unstructured":"Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19:742\u20139.","journal-title":"J Clin Oncol"},{"key":"2701_CR128","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe francaise de greffe de moelle osseuse-therapie cellulaire. J Clin Oncol. 2008;26:2512\u20138.","journal-title":"J Clin Oncol"},{"key":"2701_CR129","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol. 2024;99:1240\u20139.","journal-title":"Am J Hematol"},{"key":"2701_CR130","doi-asserted-by":"crossref","unstructured":"Nayak L, Chukwueke UN, Meehan C, Redd R, Hogan S, Lee EQ, et al. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed \/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL) Presentation at: ASCO24, 30 May\u201303 June, 2024; Chicago, Illinois, & Online. Abstract 2006.","DOI":"10.1200\/JCO.2024.42.16_suppl.2006"},{"key":"2701_CR131","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood. 2022;139:2306\u201315.","journal-title":"Blood"},{"key":"2701_CR132","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. JCO. 2019;37:2815\u201324. de noviembre de","journal-title":"JCO"},{"key":"2701_CR133","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and center for international blood and marrow transplant research analysis. Biol Blood Marrow Transpl. 2018;24:1163\u201371. junio de","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR134","unstructured":"Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Annals of Oncology [Internet]. 13 de agosto de 2024 [citado 8 de octubre de 2024];0(0). Disponible en: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)03759-1\/fulltext"},{"key":"2701_CR135","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593\u2013605. de agosto de","journal-title":"Lancet Haematol"},{"key":"2701_CR136","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365. de agosto de","journal-title":"Lancet Oncol"},{"key":"2701_CR137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103. de enero de","journal-title":"Lancet Oncol"},{"key":"2701_CR138","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325\u201332. febrero de","journal-title":"Nat Med"},{"key":"2701_CR139","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","volume":"41","author":"F Morschhauser","year":"2023","unstructured":"Morschhauser F, Dahiya S, Palomba ML, Garcia-Sancho AM, Ortega JLR, Kuruvilla J, et al. Transcend Fl: phase 2 study results of lisocabtagene maraleucel (liso-Cel) in patients (pts) with relapsed\/refractory (r\/R) follicular lymphoma (fl). Hematol Oncol. 2023;41:877\u201380.","journal-title":"Hematol Oncol"},{"key":"2701_CR140","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/bmt.2013.83","volume":"48","author":"SP Robinson","year":"2013","unstructured":"Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY, et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transpl. 2013;48:1409\u201314. noviembre de","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR141","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124:1733\u201342. 15 de abril de","journal-title":"Cancer"},{"key":"2701_CR142","first-page":"184.e1","volume":"29","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel H, et al. Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas. Transpl Cell Ther. 2023;29:184.e1\u2013184.e9. marzo de","journal-title":"Transpl Cell Ther"},{"key":"2701_CR143","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","volume":"126","author":"E Kastritis","year":"2015","unstructured":"Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126:1392\u20134. 10 de septiembre de","journal-title":"Blood"},{"key":"2701_CR144","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, Von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310. abril de","journal-title":"Lancet"},{"key":"2701_CR145","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57\u201366. enero de","journal-title":"Lancet Oncol"},{"key":"2701_CR146","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","volume":"122","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Garc\u00eda-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122:3276\u201382. de noviembre de","journal-title":"Blood"},{"key":"2701_CR147","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","volume":"124","author":"SP Treon","year":"2014","unstructured":"Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia. Blood. 2014;124:503\u201310. de julio de","journal-title":"Blood"},{"key":"2701_CR148","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","volume":"4","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up. Blood Adv. 2020;4:3952\u20139. de agosto de","journal-title":"Blood Adv"},{"key":"2701_CR149","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","volume":"36","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022;36:532\u20139. febrero de","journal-title":"Leukemia"},{"key":"2701_CR150","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. Zanubrutinib versus ibrutinib in symptomatic waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study. JCO. 2023;41:5099\u2013106. de noviembre de","journal-title":"JCO"},{"key":"2701_CR151","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gine E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"2701_CR152","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","volume":"56","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transpl. 2021;56:2911\u201321.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR153","first-page":"3494","volume":"142","author":"N Liebers","year":"2023","unstructured":"Liebers N, Finel H, Edelmann D, et al. A propensity score-matched analysis on the outcomes of brexucabtagene autoleucel from Zuma-2 study and allogeneic stem cell transplantation from the EBMT database in relapsed and refractory Post-BTKi mantle cell lymphoma [abstract]. Blood (ASH Annu Meet Abstr). 2023;142:3494.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"2701_CR154","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646\u201356.","journal-title":"Blood"},{"key":"2701_CR155","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1200\/JCO.24.00554","volume":"42","author":"O Tournilhac","year":"2024","unstructured":"Tournilhac O, Altmann B, Friedrichs B, et al. Long-term follow-up of the prospective randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma). J Clin Oncol. 2024;42:3788\u201394.","journal-title":"J Clin Oncol"},{"key":"2701_CR156","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","volume":"56","author":"E Domingo-Domenech","year":"2021","unstructured":"Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fun- goides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2021;56:1391\u2013401.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR157","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"key":"2701_CR158","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492\u20139.","journal-title":"J Clin Oncol"},{"key":"2701_CR159","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","volume":"32","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and s\u00e9zary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party extended analysis. J Clin Oncol. 2014;32:3347\u20138.","journal-title":"J Clin Oncol"},{"key":"2701_CR160","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","volume":"401","author":"A de Masson","year":"2023","unstructured":"de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d\u2019Incan M, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet. 2023;401:1941\u201350.","journal-title":"Lancet"},{"key":"2701_CR161","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet"},{"key":"2701_CR162","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"2701_CR163","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante deMedula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310\u20137.","journal-title":"Haematologica"},{"key":"2701_CR164","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","volume":"35","author":"RW Merryman","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35:2672\u201383.","journal-title":"Leukemia"},{"key":"2701_CR165","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/hematology.2021000256","volume":"2021","author":"N Epperla","year":"2021","unstructured":"Epperla N, Hamadani M. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematol Am Soc Hematol Educ Program. 2021;2021:247\u201353. Dec","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2701_CR166","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H, Ganesan N, Drill E, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021;39:3109\u201317.","journal-title":"J Clin Oncol"},{"key":"2701_CR167","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138:427\u201338.","journal-title":"Blood"},{"key":"2701_CR168","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J, McCall SJ, Fox SY, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284\u201392.","journal-title":"Lancet Oncol"},{"key":"2701_CR169","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30:612\u201320.","journal-title":"Ann Oncol"},{"key":"2701_CR170","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/bloodadvances.2023012145","volume":"8","author":"J Driessen","year":"2024","unstructured":"Driessen J, de Wit F, Herrera AF, Zinzani PL, LaCasce AS, et al. Brentuximab vedotin and chemotherapy in relapsed\/refractory Hodgkin lymphoma: a propensity score-matched analysis. Blood Adv. 2024;8:2740\u201352.","journal-title":"Blood Adv"},{"key":"2701_CR171","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1182\/blood.2022015423","volume":"139","author":"MG Mei","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139:3605\u2013316.","journal-title":"Blood"},{"key":"2701_CR172","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"2701_CR173","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/CCO.0000000000000774","volume":"33","author":"DA Eichenauer","year":"2021","unstructured":"Eichenauer DA, Engert A. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma. Curr Opin Oncol. 2021;33:395\u20139.","journal-title":"Curr Opin Oncol"},{"key":"2701_CR174","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"B Dhakal","year":"2018","unstructured":"Dhakal B, Szabo A, Chhabra S, Hamadani M, D\u2019Souza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343\u201350.","journal-title":"JAMA Oncol"},{"key":"2701_CR175","first-page":"139","volume":"68","author":"H Wiebach","year":"2020","unstructured":"Wiebach H, Gezer D, Brummendorf TH, Crysandt M, Wilop S. Tolerability of high-dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: a single-center retrospective analysis. Curr Res Transl Med. 2020;68:139\u201344.","journal-title":"Curr Res Transl Med"},{"key":"2701_CR176","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.clml.2018.05.019","volume":"18","author":"R Mina","year":"2018","unstructured":"Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, et al. Treatment intensification with autologous stem cell transplantation and lenalidomide maintenance improves survival outcomes of patients with newly diagnosed multiple myeloma in complete response. Clin Lymphoma Myeloma Leuk. 2018;18:533\u201340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2701_CR177","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.18025","volume":"197","author":"D Swan","year":"2022","unstructured":"Swan D, Hayden PJ, Eikema D, Koster L, Sauer S, Blaise D, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022;197:82\u201396. abril de","journal-title":"Br J Haematol"},{"key":"2701_CR178","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.bbmt.2016.03.021","volume":"22","author":"TE Rodriguez","year":"2016","unstructured":"Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH. Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transpl. 2016;22:1391\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR179","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","volume":"128","author":"M Cavo","year":"2016","unstructured":"Cavo M, Petrucci MT, Di Raimondo F, Zamagni E, Gamberi B, Crippa C, et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial). Blood. 2016;128:991.","journal-title":"Blood"},{"key":"2701_CR180","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.V128.22.673.673","volume":"128","author":"M Cavo","year":"2016","unstructured":"Cavo M, Beksac M, Dimopoulos MA, Pantani L, Gay F, H\u00e1jek R, et al. Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, Phase III Study of the European Myeloma Network (EMN02\/HO95 MM Trial). Blood. 2016;128:673.","journal-title":"Blood"},{"key":"2701_CR181","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782\u201391.","journal-title":"N Engl J Med"},{"key":"2701_CR182","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"2701_CR183","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","volume":"35","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia 2021;35:1134\u201344. abril de","journal-title":"Leukemia"},{"key":"2701_CR184","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"G Cook","year":"2014","unstructured":"Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874\u201385. julio de","journal-title":"Lancet Oncol"},{"key":"2701_CR185","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","volume":"18","author":"VH Jimenez-Zepeda","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transpl. 2012;18:773\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR186","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/leu.2016.101","volume":"30","author":"M Sobh","year":"2016","unstructured":"Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Sch\u00f6nland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30:2047\u201354.","journal-title":"Leukemia"},{"key":"2701_CR187","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110\u201320.","journal-title":"N Engl J Med"},{"key":"2701_CR188","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","volume":"121","author":"G Gahrton","year":"2013","unstructured":"Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT- NMAM2000 study. Blood. 2013;121:5055\u201363.","journal-title":"Blood"},{"key":"2701_CR189","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"L Rosinol","year":"2008","unstructured":"Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591\u20133.","journal-title":"Blood"},{"key":"2701_CR190","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bbmt.2011.07.026","volume":"18","author":"F Patriarca","year":"2012","unstructured":"Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transpl. 2012;18:617\u201326.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR191","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.bbmt.2017.07.003","volume":"23","author":"N Ghosh","year":"2017","unstructured":"Ghosh N, Ye X, Tsai HL, Bola\u00f1os-Meade J, Fuchs EJ, Luznik L, et al. Allogeneic blood or marrow transplantation with post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis in multiple myeloma. Biol Blood Marrow Transpl. 2017;23:1903\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR192","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","volume":"32","author":"D Beauvais","year":"2020","unstructured":"Beauvais D, Danhof S, Hayden PJ, Einsele H, Yakoub-Agha I. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma. Curr Opin Oncol. 2020;32:418\u201326.","journal-title":"Curr Opin Oncol"},{"key":"2701_CR193","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2701_CR194","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2701_CR195","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. JCO. 2023;41:1265\u201374. de febrero de","journal-title":"JCO"},{"key":"2701_CR196","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","volume":"103","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960\u20133.","journal-title":"Blood"},{"key":"2701_CR197","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","volume":"96","author":"E Muchtar","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, et al. Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement 2020 update. Mayo Clin Proc. 2021;96:1546\u201377. junio de","journal-title":"Mayo Clin Proc"},{"key":"2701_CR198","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa070484","volume":"357","author":"A Jaccard","year":"2007","unstructured":"Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083\u201393.","journal-title":"N Engl J Med"},{"key":"2701_CR199","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","volume":"33","author":"A D\u2019Souza","year":"2015","unstructured":"D\u2019Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741\u20139.","journal-title":"J Clin Oncol"},{"key":"2701_CR200","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","volume":"36","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36:1323\u20139.","journal-title":"J Clin Oncol"},{"key":"2701_CR201","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","volume":"128","author":"T Bochtler","year":"2016","unstructured":"Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128:594\u2013602.","journal-title":"Blood"},{"key":"2701_CR202","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2141.2009.07842.x","volume":"147","author":"JC Marsh","year":"2009","unstructured":"Marsh JC, Ball SE, Cavenagh J, Derbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43\u201370.","journal-title":"Br J Haematol"},{"key":"2701_CR203","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","volume":"120","author":"P Scheinberg","year":"2012","unstructured":"Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120:1185\u201396.","journal-title":"Blood"},{"key":"2701_CR204","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","volume":"131","author":"S Giammarco","year":"2018","unstructured":"Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, et al. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018;131:1989\u201392.","journal-title":"Blood"},{"key":"2701_CR205","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2024-194713","volume":"144","author":"AM Risitano","year":"2024","unstructured":"Risitano AM, Eikema DJ, Tuffnell J, Piepenbroek B, Potter V, Sicre De Fontbrune F, et al. Role of age and donor type in 3646 severe aplastic anemia patients undergoing hematopoietic stem cell transplantation in 2011-2020: a retrospective EBMT-Saawp study. Blood. 2024;144:595\u2013595. de noviembre de","journal-title":"Blood"},{"key":"2701_CR206","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","volume":"97","author":"A Bacigalupo","year":"2012","unstructured":"Bacigalupo A, Soci\u00e9 G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, et al. Bone marrow versus peripheral blood matched sibling transplants, in acquired aplastic anemia: survival advantage for marrow in all age groups. Haematologica. 2012;97:1142\u20138.","journal-title":"Haematologica"},{"key":"2701_CR207","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2010-12-327536","volume":"118","author":"JC Marsh","year":"2011","unstructured":"Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anaemia. Blood. 2011;118:2351\u20137.","journal-title":"Blood"},{"key":"2701_CR208","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/bmt.2013.115","volume":"49","author":"JC Marsh","year":"2014","unstructured":"Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ, et al. Retrospective study of Alemtuzumab versus ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anaemia: a study from the British Society for Blood and Marrow Transplantation (BSBMT). Bone Marrow Transpl. 2014;49:42\u201348.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR209","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540\u201350. de abril de","journal-title":"N Engl J Med"},{"key":"2701_CR210","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault De Latour","year":"2022","unstructured":"Peffault De Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386:11\u201323. de enero de","journal-title":"N Engl J Med"},{"key":"2701_CR211","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2024-206632","volume":"144","author":"D Kaya","year":"2024","unstructured":"Kaya D, Cook R, Iacobelli S, Kulasekararaj AG, Napolitani G, Gerlevik S, et al. Dynamics of oligoclonal hematopoiesis in severe aplastic anemia patients undergoing immunosuppressive treatment: longitudinal somatic mutation analysis from the EBMT race trial. Blood. 2024;144:33\u201333. de noviembre de","journal-title":"Blood"},{"key":"2701_CR212","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/bmt.2012.233","volume":"48","author":"A Bacigalupo","year":"2013","unstructured":"Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor trans- plantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transpl. 2013;48:198\u2013200.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR213","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/asheducation-2016.1.90","volume":"2016","author":"RP de Latour","year":"2016","unstructured":"de Latour RP. Transplantation for bone marrow failure: current issues. Hematology Am Soc Hematol Educ Program. 2016;2016:90\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2701_CR214","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11\u201319.","journal-title":"N Engl J Med"},{"key":"2701_CR215","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818\u201325.","journal-title":"Blood"},{"key":"2701_CR216","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3324\/haematol.2017.176339","volume":"103","author":"E Lengline","year":"2018","unstructured":"Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103:212\u201320.","journal-title":"Haematologica"},{"key":"2701_CR217","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","volume":"23","author":"AE DeZern","year":"2017","unstructured":"DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017;23:498\u2013504. marzo de","journal-title":"Biol Blood Marrow Transplant"},{"key":"2701_CR218","first-page":"78","volume":"1","author":"R Peffault de Latour","year":"2010","unstructured":"Peffault de Latour R, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anaemia. A study by Eurocord and the Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2010;1:78\u201385.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR219","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/bmt.2012.252","volume":"48","author":"RP De Latour","year":"2013","unstructured":"De Latour RP, Rocha V, Socie G. Cord blood transplantation in aplastic anaemia. Bone Marrow Transpl. 2013;48:201\u20132.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR220","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/bmt.2012.231","volume":"48","author":"F Ciceri","year":"2013","unstructured":"Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haploidentical transplantation in patients with acquired aplastic anaemia. Bone Marrow Transpl. 2013;48:183\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR221","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","volume":"20","author":"J Clay","year":"2014","unstructured":"Clay J, Kulasekarara AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Non- myeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2014;20:1711\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR222","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.bbmt.2017.08.004","volume":"23","author":"S Pagliuca","year":"2017","unstructured":"Pagliuca S, Peffault de Latour R, Volt F, Locatelli F, Zecca M, Dalle JH, et al. Long-term outcomes of cord blood transplantation from an HLA-identical sibling for patients with bone marrow failure syndromes: a report from Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2017;23:1939\u201348.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR223","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/asheducation-2018.1.467","volume":"2018","author":"A Bacigalupo","year":"2018","unstructured":"Bacigalupo A. Alternative donor transplants for severe aplastic anemia. Hematol Am Soc Hematol Educ Program. 2018;2018:467\u201373.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2701_CR224","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2024024173","volume":"144","author":"J Montoro","year":"2024","unstructured":"Montoro J, Eikema DJ, Tuffnell J, Potter V, Kalwak K, Halkes CJM, et al. Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT. Blood. 2024;144:323\u201333. 18 de julio de","journal-title":"Blood"},{"key":"2701_CR225","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","volume":"55","author":"PH Prata","year":"2020","unstructured":"Prata PH, Eikema DJ, Afansyev B, Bosman P, Smiers F, Diez-Martin JL, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transpl. 2020;55:1050\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR226","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","volume":"4","author":"AE DeZern","year":"2020","unstructured":"DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4:1770\u20139. de abril de","journal-title":"Blood Adv"},{"key":"2701_CR227","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","volume":"9","author":"AE DeZern","year":"2022","unstructured":"DeZern AE, Eapen M, Wu J, Talano JA, Solh M, D\u00e1vila Salda\u00f1a BJ, et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9:e660\u20139. septiembre de","journal-title":"Lancet Haematol"},{"key":"2701_CR228","doi-asserted-by":"crossref","unstructured":"DeZern A, Zahurak ML, Symons HJ, Cooke KR, Huff CA, Jain T, et al. Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood Journal. de abril de 2023;blood.2023020435.","DOI":"10.1182\/blood.2023020435"},{"key":"2701_CR229","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1182\/bloodadvances.2023011642","volume":"8","author":"DV Babushok","year":"2024","unstructured":"Babushok DV, DeZern AE, De Castro CM, Rogers ZR, Beenhouwer D, Broder MS, et al. Modified Delphi panel consensus recommendations for management of severe aplastic anemia. Blood Adv. 2024;8:3946\u201360. de agosto de","journal-title":"Blood Adv"},{"key":"2701_CR230","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jtct.2024.09.017","volume":"30","author":"R Iftikhar","year":"2024","unstructured":"Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM, et al. Allogeneic hematopoietic cell transplantation for the treatment of severe aplastic anemia: evidence-based guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30:1155\u201370. diciembre de","journal-title":"Transplant Cell Ther"},{"key":"2701_CR231","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1182\/bloodadvances.2024013529","volume":"8","author":"P Scheinberg","year":"2024","unstructured":"Scheinberg P, Kulasekararaj AG. Consensus recommendations for severe aplastic anemia. Blood Adv. 2024;8:5719\u201320. de noviembre de","journal-title":"Blood Adv"},{"key":"2701_CR232","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3324\/haematol.2023.284022","volume":"109","author":"AE DeZern","year":"2023","unstructured":"DeZern AE, Zahurak M, Jones RJ, Brodsky RA. Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia. Haematologica2023;109:657\u201360. de septiembre de","journal-title":"Haematologica"},{"key":"2701_CR233","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bjh.17753","volume":"196","author":"AM Risitano","year":"2022","unstructured":"Risitano AM, Peffault De Latour R. How we(\u2019ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol. 2022;196:288\u2013303. enero de","journal-title":"Br J Haematol"},{"key":"2701_CR234","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.smim.2022.101618","volume":"59","author":"AM Risitano","year":"2022","unstructured":"Risitano AM, Peffault De Latour R, Marano L, Frieri C. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls. Semin Immunol 2022;59:101618. enero de","journal-title":"Semin Immunol"},{"key":"2701_CR235","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. de junio de","journal-title":"Front Immunol"},{"key":"2701_CR236","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajh.25016","volume":"93","author":"AM Risitano","year":"2018","unstructured":"Risitano AM, Marotta S. Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2018;93:564\u201377. agosto de","journal-title":"Am J Hematol"},{"key":"2701_CR237","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3324\/haematol.2012.062828","volume":"97","author":"PR de Latour","year":"2012","unstructured":"de Latour PR, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97:1666\u201373.","journal-title":"Haematologica"},{"key":"2701_CR238","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804\u201311.","journal-title":"Blood"},{"key":"2701_CR239","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2024-194716","volume":"144","author":"C Frieri","year":"2024","unstructured":"Frieri C, Eikema DJ, Tuffnell J, Piepenbroek B, Benakli M, Helbig G, et al. Improved outcomes in paroxysmal nocturnal hemoglobinuria patients undergoing allogeneic hematopoietic stem cell transplantation in 2011\u20132020: a retrospective EBMT-Saawp study. Blood. 2024;144:305\u2013305. de noviembre de","journal-title":"Blood"},{"key":"2701_CR240","unstructured":"Pellegrini M. Access to expensive drugs in EU countries for very rare hematological blood disorders: the example of paroxysmal nocturnal hemoglobinuria. A survey by ERN-EUROBLOODNET. En EHA 2024;"},{"key":"2701_CR241","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol. 2024;204:784\u2013804. marzo de","journal-title":"Br J Haematol"},{"key":"2701_CR242","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/annonc\/mdl086","volume":"17","author":"L Barkholt","year":"2006","unstructured":"Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol. 2006;17:1134\u201340.","journal-title":"Ann Oncol"},{"key":"2701_CR243","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1182\/blood-2005-10-3945","volume":"107","author":"F Carnevale-Schianca","year":"2006","unstructured":"Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood. 2006;107:3795\u2013803.","journal-title":"Blood"},{"key":"2701_CR244","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3324\/haematol.10521","volume":"92","author":"S Secondino","year":"2007","unstructured":"Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F.European Group for Blood and Marrow Transplantation Solid Tumors Working Party et al. Reduced-intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica. 2007;92:418\u201320.","journal-title":"Haematologica"},{"key":"2701_CR245","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/annonc\/mdz285","volume":"30","author":"P Comoli","year":"2019","unstructured":"Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, et al. Development of adaptive immune effector therapies in solid tumors. Ann Oncol. 2019;30:1740\u201350.","journal-title":"Ann Oncol"},{"key":"2701_CR246","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2023.12.009","volume":"35","author":"P Comoli","year":"2024","unstructured":"Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart JE.EBMT Cellular Therapy & Immunobiology Working Party; European Society of Medical Oncology et al. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Ann Oncol. 2024;35:404\u20136.","journal-title":"Ann Oncol"},{"key":"2701_CR247","doi-asserted-by":"crossref","unstructured":"Haanen JB, Mackensen A, Schultze-Florey C, Alsdorf W, Wagner-Drouet E, Heudobler D, et al. Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating the safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed\/refractory CLDN6+ solid tumors. ESMO Congress, Barcelona September 2024, Abstract 611O.","DOI":"10.1016\/j.annonc.2024.08.678"},{"key":"2701_CR248","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"13","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 2024;13:1460\u201371.","journal-title":"Lancet"},{"key":"2701_CR249","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1126\/science.adp1130","volume":"385","author":"SA Rosenberg","year":"2024","unstructured":"Rosenberg SA. Lymphocytes as a living drug for cancer. Science. 2024;385:25\u201326.","journal-title":"Science"},{"key":"2701_CR250","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208475","volume":"14","author":"S Secondino","year":"2023","unstructured":"Secondino S, Pedrazzoli P, Basso S, Bossi P, Bianco A, Imarisio I, et al. Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma. Front Immunol. 2023;14:1208475.","journal-title":"Front Immunol"},{"key":"2701_CR251","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.3390\/cancers15143667","volume":"15","author":"S Secondino","year":"2023","unstructured":"Secondino S, Canino C, Alaimo D, Muzzana M, Galli G, Borgetto S, et al. Clinical trials of cellular therapies in solid tumors. Cancers. 2023;15:3667.","journal-title":"Cancers"},{"key":"2701_CR252","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","volume":"28","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Afamitresgene Autoleucel: first approval. Mol Diagn Ther. 2024;28:861\u20136.","journal-title":"Mol Diagn Ther"},{"key":"2701_CR253","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1200\/JCO.2010.32.5910","volume":"29","author":"DA Berry","year":"2011","unstructured":"Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, et al. High-dose chemotherapy with autologous stem cell support versus standard-dose chemotherapy: overview of individual patient data from 15 randomized adjuvant therapy breast cancer trials. J Clin Oncol. 2011;29:3214\u201323.","journal-title":"J Clin Oncol"},{"key":"2701_CR254","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1200\/JCO.2010.32.5936","volume":"29","author":"DA Berry","year":"2011","unstructured":"Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011;29:3224\u201331.","journal-title":"J Clin Oncol"},{"key":"2701_CR255","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/bmt.2012.149","volume":"48","author":"M Martino","year":"2013","unstructured":"Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C, et al. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transpl. 2013;48:414\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR256","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0140-6736(05)67784-7","volume":"366","author":"UA Nitz","year":"2005","unstructured":"Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, et al. West German Study Group. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366:1935\u201344.","journal-title":"Lancet"},{"key":"2701_CR257","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.bbmt.2015.12.011","volume":"22","author":"M Martino","year":"2016","unstructured":"Martino M, Lanza F, Pavesi L, \u00d6zt\u00fcrk M, Blaise D, Leno N\u00fa\u00f1ez R, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in high-risk breast cancer: data from the European Group for Blood and Marrow Transplantation Registry. Biol Blood Marrow Transpl. 2016;22:475\u201381.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR258","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jamaoncol.2019.6276","volume":"6","author":"TG Steenbruggen","year":"2020","unstructured":"Steenbruggen TG, Steggink LC, Seynaeve CM, van der Hoeven JJM, Hooning MJ, Jager A, et al. High-dose chemotherapy with hematopoietic stem cell transplant in patients with high-risk breast cancer and 4 or more involved axillary lymph nodes\u201420-year follow-up of a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:528\u201334. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6276","journal-title":"JAMA Oncol"},{"key":"2701_CR259","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1517\/14712598.2015.963051","volume":"15","author":"A Necchi","year":"2015","unstructured":"Necchi A, Lanza F, Rosti G, Martino M, Far\u00e8 E, Pedrazzoli P. European Society for Blood and Marrow Transplantation, Solid Tumors Working Party (EBMT- STWP) and the Italian Germ Cell Cancer Group (IGG) High-dose chemotherapy for germ cell tumors: do we have a model? Expert Opin Biol Ther. 2015;15:33\u201344.","journal-title":"Expert Opin Biol Ther"},{"key":"2701_CR260","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1002\/cncr.33771","volume":"127","author":"V Agrawal","year":"2021","unstructured":"Agrawal V, Abonour R, Abu Zaid M, Althouse SK, Ashkar R, Albany C, et al. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation. Cancer. 2021;127:3751\u201360. https:\/\/doi.org\/10.1002\/cncr.33771","journal-title":"Cancer"},{"key":"2701_CR261","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","volume":"29","author":"A Lorch","year":"2011","unstructured":"Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29:2178\u201384.","journal-title":"J Clin Oncol"},{"key":"2701_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103692","volume":"9","author":"S Secondino","year":"2024","unstructured":"Secondino S, Badoglio M, Rosti G, Labopin M, Delaye M, Bokemeyer C, et al. High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT. ESMO Open. 2024;9:103692.","journal-title":"ESMO Open"},{"key":"2701_CR263","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","volume":"28","author":"R Ladenstein","year":"2010","unstructured":"Ladenstein R, P\u00f6tschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284\u201391.","journal-title":"J Clin Oncol"},{"key":"2701_CR264","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000860","volume":"5","author":"CE Heilig","year":"2020","unstructured":"Heilig CE, Badoglio M, Labopin M, Fr\u00f6hling S, Secondino S, Heinz J, et al. Hae- matopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open. 2020;5:e000860.","journal-title":"ESMO Open"},{"key":"2701_CR265","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.ejca.2005.02.022","volume":"41","author":"F Spreafico","year":"2005","unstructured":"Spreafico F, Massimino M, Gandola L, Cefalo G, Mazza E, Landonio G, et al. Survival of adults treated for medulloblastoma using paediatric protocols. Eur J Cancer. 2005;41:1304\u201310.","journal-title":"Eur J Cancer"},{"key":"2701_CR266","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","volume":"57","author":"T Alexander","year":"2022","unstructured":"Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2022;57:1055\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR267","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","volume":"74","author":"PA Muraro","year":"2017","unstructured":"Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74:459\u201369.","journal-title":"JAMA Neurol"},{"key":"2701_CR268","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","volume":"321","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321:165\u201374.","journal-title":"JAMA"},{"key":"2701_CR269","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/s41409-019-0747-2","volume":"55","author":"P Tappenden","year":"2020","unstructured":"Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, et al. Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2020;55:1473\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR270","doi-asserted-by":"publisher","first-page":"e1215","DOI":"10.1212\/WNL.0000000000011461","volume":"96","author":"G Boffa","year":"2021","unstructured":"Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2021;96:e1215\u2013e26.","journal-title":"Neurology"},{"key":"2701_CR271","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1177\/1352458520985238","volume":"27","author":"J Das","year":"2021","unstructured":"Das J, Snowden JA, Burman J, Freedman MS, Atkins H, Bowman M, et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with \u00abaggressive\u00bb multiple sclerosis. Mult Scler. 2021;27:1198\u2013204.","journal-title":"Mult Scler"},{"key":"2701_CR272","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498\u2013506.","journal-title":"Lancet"},{"key":"2701_CR273","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490\u20138.","journal-title":"JAMA"},{"key":"2701_CR274","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35\u201347.","journal-title":"N Engl J Med"},{"key":"2701_CR275","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2021;106:375\u201383.","journal-title":"Haematologica"},{"key":"2701_CR276","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","volume":"56","author":"RK Burt","year":"2021","unstructured":"Burt RK, Han X, Quigley K, Arnautovic I, Shah SJ, Lee DC, et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transpl. 2021;56:50\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR277","doi-asserted-by":"crossref","unstructured":"Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder\u2014recommendations from ECTRIMS and the EBMT. Nat Rev Neurol. 2025.","DOI":"10.1038\/s41582-024-01050-x"},{"key":"2701_CR278","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.2015.16700","volume":"314","author":"CJ Hawkey","year":"2015","unstructured":"Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, et al. Autologous hematopoetic stem cell transplantation for refractory crohn disease: a randomized clinical trial. Jama. 2015;314:2524\u201334.","journal-title":"Jama"},{"key":"2701_CR279","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2468-1253(23)00460-0","volume":"9","author":"JO Lindsay","year":"2024","unstructured":"Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur CU, et al. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn\u2019s disease (ASTIClite): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:333\u201345.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2701_CR280","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113:214\u201323.","journal-title":"Blood"},{"key":"2701_CR281","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","volume":"53","author":"RK Burt","year":"2018","unstructured":"Burt RK, Han X, Gozdziak P, Yaung K, Morgan A, Clendenan AM, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transpl. 2018;53:692\u2013700.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR282","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/0961203312470729","volume":"22","author":"B Alchi","year":"2013","unstructured":"Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus. 2013;22:245\u201353.","journal-title":"Lupus"},{"key":"2701_CR283","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1352458514541978","volume":"21","author":"R Greco","year":"2015","unstructured":"Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015;21:189\u201397.","journal-title":"Mult Scler"},{"key":"2701_CR284","doi-asserted-by":"publisher","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","volume":"93","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93:e1732\u2013e41.","journal-title":"Neurology"},{"key":"2701_CR285","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","volume":"267","author":"RK Burt","year":"2020","unstructured":"Burt RK, Balabanov R, Tavee J, Han X, Sufit R, Ajroud-Driss S, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2020;267:3378\u201391.","journal-title":"J Neurol"},{"key":"2701_CR286","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","volume":"73","author":"A Bryant","year":"2016","unstructured":"Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol. 2016;73:652\u20138.","journal-title":"JAMA Neurol"},{"key":"2701_CR287","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00415-020-10054-8","volume":"268","author":"L Kass-Iliyya","year":"2021","unstructured":"Kass-Iliyya L, Snowden JA, Thorpe A, Jessop H, Chantry AD, Sarrigiannis PG, et al. Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. J Neurol. 2021;268:265\u201375.","journal-title":"J Neurol"},{"key":"2701_CR288","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1212\/WNL.0000000000011338","volume":"96","author":"RK Burt","year":"2021","unstructured":"Burt RK, Balabanov R, Han X, Quigley K, Arnautovic I, Helenowski I, et al. Autologous hematopoietic stem cell transplantation for stiff-person spectrum disorder: a clinical trial. Neurology. 2021;96:e817\u2013e30.","journal-title":"Neurology"},{"key":"2701_CR289","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41409-019-0763-2","volume":"55","author":"T Alexander","year":"2020","unstructured":"Alexander T, Samuelson C, Daikeler T, Henes J, Akil M, Skagerlind L, et al. Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. Bone Marrow Transpl. 2020;55:1512\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR290","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/s41409-020-0907-4","volume":"55","author":"C Laurent","year":"2020","unstructured":"Laurent C, Marjanovic Z, Ricard L, Henes J, Dulery R, Badoglio M, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2020;55:2109\u201313.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR291","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638709","volume":"12","author":"M Puyade","year":"2021","unstructured":"Puyade M, Patel A, Lim YJ, Blank N, Badoglio M, Gualandi F, et al. Autologous hematopoietic stem cell transplantation for Beh\u00e7et\u2019s Disease: a retrospective survey of patients treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Front Immunol. 2021;12:638709.","journal-title":"Front Immunol"},{"key":"2701_CR292","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/2050640616646529","volume":"5","author":"P Nijeboer","year":"2017","unstructured":"Nijeboer P, van Wanrooij R, van Gils T, Wierdsma NJ, Tack GJ, Witte BI, et al. Lymphoma development and survival in refractory coeliac disease type II: histological response as prognostic factor. U Eur Gastroenterol J. 2017;5:208\u201317.","journal-title":"U Eur Gastroenterol J"},{"key":"2701_CR293","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"JA Snowden","year":"2017","unstructured":"Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1:2742\u201355.","journal-title":"Blood Adv"},{"key":"2701_CR294","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102404","volume":"45","author":"RK Burt","year":"2020","unstructured":"Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, et al. Health economics and patient outcomes of hematopoietic stem cell transplantation virsus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Mult Scler Relat Disord. 2020;45:102404.","journal-title":"Mult Scler Relat Disord"},{"key":"2701_CR295","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.645263","volume":"12","author":"RK Burt","year":"2021","unstructured":"Burt RK, Tappenden P, Balabanov R, Han X, Quigley K, Snowden JA, et al. The cost-effectiveness of immunoglobulin vs. hematopoietic stem cell transplantation for CIDP. Front Neurol. 2021;12:645263.","journal-title":"Front Neurol"},{"key":"2701_CR296","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, et al. Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP working parties. Front Immunol. 2019;10:1570.","journal-title":"Front Immunol"},{"key":"2701_CR297","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"B Sharrack","year":"2020","unstructured":"Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transpl. 2020;55:283\u2013306.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR298","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2017.56","volume":"52","author":"D Farge","year":"2017","unstructured":"Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transpl. 2017;52:1495\u2013503.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR299","doi-asserted-by":"crossref","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, \u010coli\u0107 J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2024.","DOI":"10.1136\/ard-2024-226430"},{"key":"2701_CR300","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ecco-jcc\/jjx184","volume":"12","author":"JA Snowden","year":"2018","unstructured":"Snowden JA, Pan\u00e9s J, Alexander T, Allez M, Ardizzone S, Dierickx D, et al. Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn\u2019s Disease: A Review on Behalf of ECCO and EBMT. J Crohns Colitis. 2018;12:476\u201388.","journal-title":"J Crohns Colitis"},{"key":"2701_CR301","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41409-019-0430-7","volume":"54","author":"H Jessop","year":"2019","unstructured":"Jessop H, Farge D, Saccardi R, Alexander T, Rovira M, Sharrack B, et al. General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transpl. 2019;54:933\u201342.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR302","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556141","volume":"11","author":"F Roberts","year":"2020","unstructured":"Roberts F, Hobbs H, Jessop H, Bozzolini C, Burman J, Greco R, et al. Rehabilitation before and after Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for patients with Multiple Sclerosis (MS): consensus guidelines and recommendations for best clinical practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). Front Neurol. 2020;11:556141.","journal-title":"Front Neurol"},{"key":"2701_CR303","doi-asserted-by":"publisher","unstructured":"Alexander T, Roldan E, Del Papa N, Farge D, Henes J, Marjanovic Z, et al. Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines committee. Bone Marrow Transpl. 2025; https:\/\/doi.org\/10.1038\/s41409-025-02695-y (Online ahead of print).","DOI":"10.1038\/s41409-025-02695-y"},{"key":"2701_CR304","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41409-021-01326-6","volume":"56","author":"R Greco","year":"2021","unstructured":"Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, et al. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transpl. 2021;56:1493\u2013508.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR305","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ana.27029","volume":"96","author":"G Brittain","year":"2024","unstructured":"Brittain G, Roldan E, Alexander T, Saccardi R, Snowden JA, Sharrack B, et al. The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases. Ann Neurol. 2024;96:441\u201352.","journal-title":"Ann Neurol"},{"key":"2701_CR306","doi-asserted-by":"crossref","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023.","DOI":"10.1016\/S0140-6736(23)01126-1"},{"key":"2701_CR307","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385:567\u20139.","journal-title":"N Engl J Med"},{"key":"2701_CR308","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"2701_CR309","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D, et al. Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med. 2024;391:376\u20138.","journal-title":"N Engl J Med"},{"key":"2701_CR310","doi-asserted-by":"crossref","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2024.","DOI":"10.1016\/S2665-9913(24)00282-0"},{"key":"2701_CR311","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F Muller","year":"2023","unstructured":"Muller F, Boeltz S, Knitza J, Aigner M, Volkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401:815\u20138.","journal-title":"Lancet"},{"key":"2701_CR312","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329:2154\u201362.","journal-title":"JAMA"},{"key":"2701_CR313","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187:4890\u2013904.e9.","journal-title":"Cell"},{"key":"2701_CR314","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.beproc.2020.104155","volume":"177","author":"L Wang","year":"2020","unstructured":"Wang L, Luo YC, Wang H, Zou YB, Yao HQ, Ullah S, et al. Azure-winged magpies fail to understand the principle of mirror imaging. Behav Process. 2020;177:8.","journal-title":"Behav Process"},{"key":"2701_CR315","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Pappa V, Motte J, et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis. 2024;83:1597\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2701_CR316","doi-asserted-by":"crossref","unstructured":"Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O, et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann Rheum Dis. 2024.","DOI":"10.1136\/ard-2024-226437"},{"key":"2701_CR317","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, Bottcher M, Desel C, Borie D, et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 2023;22:1104\u20135.","journal-title":"Lancet Neurol"},{"key":"2701_CR318","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5:550\u20138 e2.","journal-title":"Med"},{"key":"2701_CR319","doi-asserted-by":"publisher","first-page":"e2403227121","DOI":"10.1073\/pnas.2403227121","volume":"121","author":"S Faissner","year":"2024","unstructured":"Faissner S, Motte J, Sgodzai M, Geis C, Haghikia A, Mougiakakos D, et al. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci USA. 2024;121:e2403227121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2701_CR320","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8:5.","journal-title":"Signal Transduct Target Ther"},{"key":"2701_CR321","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovic MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22:578\u201390.","journal-title":"Lancet Neurol"},{"key":"2701_CR322","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.2020008187","volume":"138","author":"SO Burns","year":"2021","unstructured":"Burns SO, Morris EC. How I use allogeneic HSCT for adults with inborn errors of immunity. Blood. 2021;138:1666\u201376. de noviembre de","journal-title":"Blood"},{"key":"2701_CR323","doi-asserted-by":"crossref","unstructured":"Baronciani D. Age is a crucial determinant of GFRS with incidence of severe chronic GVHD reducing over time in haemopoietic cell transplantation for transfusion dependent thalassaemia: real world data from 2010\u20132021. an analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party. ASH 2024 Abstract. En.","DOI":"10.1182\/blood-2024-208421"},{"key":"2701_CR324","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.24674","volume":"92","author":"E Angelucci","year":"2017","unstructured":"Angelucci E, Pilo F, Coates TD. Transplantation in thalassemia: revisiting the Pesaro risk factors 25 years later. Am J Hematol 2017;92:411\u20133. mayo de","journal-title":"Am J Hematol"},{"key":"2701_CR325","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2013.099747","volume":"99","author":"E Angelucci","year":"2014","unstructured":"Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014;99:811\u201320. de mayo de","journal-title":"Haematologica"},{"key":"2701_CR326","doi-asserted-by":"crossref","unstructured":"De La Fuente J. Significant growth in HCT use for haemoglobinopathies in the last decade driven by sickle cell disease across all ages with excellent outcomes: an analysis of EBMT Haemoglobinopathies Working Party. ASH 2024 Abstract. En.","DOI":"10.1182\/blood-2024-208191"},{"key":"2701_CR327","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2010-01-261800","volume":"116","author":"D Niewerth","year":"2010","unstructured":"Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205\u201314.","journal-title":"Blood"},{"key":"2701_CR328","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bbmt.2013.04.001","volume":"19","author":"MJ Burke","year":"2013","unstructured":"Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transpl. 2013;19:1021\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR329","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3324\/haematol.2011.051714","volume":"97","author":"JH Klusmann","year":"2012","unstructured":"Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica. 2012;97:21\u201329.","journal-title":"Haematologica"},{"key":"2701_CR330","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/leu.2011.267","volume":"26","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012;26:654\u201361.","journal-title":"Leukemia"},{"key":"2701_CR331","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clim.2009.04.009","volume":"133","author":"F Locatelli","year":"2009","unstructured":"Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol. 2009;133:171\u20138.","journal-title":"Clin Immunol"},{"key":"2701_CR332","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2141.2006.06140.x","volume":"134","author":"D Marks","year":"2006","unstructured":"Marks D, Khattry N, Cummins M, Goulden N, Green A, Harvey J, et al. Haploi- dentical stem cell transplantation for children with acute leukaemia. Br J Haematol. 2006;134:196\u2013201.","journal-title":"Br J Haematol"},{"key":"2701_CR333","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.12900","volume":"166","author":"H Hasle","year":"2014","unstructured":"Hasle H. A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol. 2014;166:23\u201333.","journal-title":"Br J Haematol"},{"key":"2701_CR334","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","volume":"116","author":"G Mann","year":"2010","unstructured":"Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010;116:2644\u201350.","journal-title":"Blood"},{"key":"2701_CR335","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","volume":"47","author":"A von Stackelberg","year":"2011","unstructured":"von Stackelberg A, Volzke E, Kuhl JS, Seeger K, Schrauder A, Escherich G, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer. 2011;47:90\u201397.","journal-title":"Eur J Cancer"},{"key":"2701_CR336","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pcl.2010.01.004","volume":"57","author":"C Peters","year":"2010","unstructured":"Peters C, Cornish JM, Parikh SH, Kurtzberg J. Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia. Pedia Clin North Am. 2010;57:27\u201346.","journal-title":"Pedia Clin North Am"},{"key":"2701_CR337","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/bmt.2008.58","volume":"41","author":"A Schrauder","year":"2008","unstructured":"Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transpl. 2008;41:S71\u201374.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR338","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","volume":"33","author":"C Peters","year":"2015","unstructured":"Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors\u2014The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2701_CR339","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1016\/j.bbmt.2010.10.005","volume":"17","author":"MA Pulsipher","year":"2011","unstructured":"Pulsipher MA, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leuke- mia: to transplant or not to transplant? Biol Blood Marrow Transpl. 2011;17:S137\u2013148.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR340","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prog- nostic value of minimal residual disease quantification before allogeneic stem- cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27:377\u201384.","journal-title":"J Clin Oncol"},{"key":"2701_CR341","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","volume":"31","author":"C Eckert","year":"2013","unstructured":"Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grumayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736\u201342.","journal-title":"J Clin Oncol"},{"key":"2701_CR342","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33:1275\u201384.","journal-title":"J Clin Oncol"},{"key":"2701_CR343","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/bmt.2010.217","volume":"46","author":"JC Beck","year":"2011","unstructured":"Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, et al. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transpl. 2011;46:950\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR344","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2012-12-469668","volume":"121","author":"R Meisel","year":"2013","unstructured":"Meisel R, Klingebiel T, Dilloo D. German\/Austrian Pediatric Registry for Stem Cell Transplantation Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation. Blood. 2013;121:863\u20135.","journal-title":"Blood"},{"key":"2701_CR345","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority Phase III study. J Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol"},{"key":"2701_CR346","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/bloodadvances.2024014548","volume":"9","author":"K Kalwak","year":"2025","unstructured":"Kalwak K, Moser L, Poetschger U, et al. Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL. Results of FORUM. Blood Adv. 2025;9:741\u201351. https:\/\/doi.org\/10.1182\/bloodadvances.2024014548. Feb","journal-title":"Blood Adv"},{"key":"2701_CR347","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11899-012-0113-6","volume":"7","author":"M Suttorp","year":"2012","unstructured":"Suttorp M, Eckardt L, Tauer JT, Millot F. Management of chronic myeloid leukemia in childhood. Curr Hematol Malign Rep. 2012;7:116\u201324.","journal-title":"Curr Hematol Malign Rep"},{"key":"2701_CR348","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.bbmt.2010.09.003","volume":"17","author":"M Suttorp","year":"2011","unstructured":"Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transpl. 2011;17:S115\u2013122.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR349","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bjh.12977","volume":"167","author":"J de la Fuente","year":"2014","unstructured":"de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167:33\u201347.","journal-title":"Br J Haematol"},{"key":"2701_CR350","doi-asserted-by":"publisher","first-page":"721","DOI":"10.12659\/MSM.883599","volume":"18","author":"BA Jaeger","year":"2012","unstructured":"Jaeger BA, Tauer JT, Ulmer A, Kuhlisch E, Roth HJ, Suttorp M. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit. 2012;18:721\u20138.","journal-title":"Med Sci Monit"},{"key":"2701_CR351","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0033-1343483","volume":"225","author":"A Ulmer","year":"2013","unstructured":"Ulmer A, Tabea Tauer J, Glauche I, Jung R, Suttorp M. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model. Klin Padiatr. 2013;225:120\u20136.","journal-title":"Klin Padiatr"},{"key":"2701_CR352","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0029-1239529","volume":"221","author":"M Suttorp","year":"2009","unstructured":"Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr. 2009;221:351\u20137.","journal-title":"Klin Padiatr"},{"key":"2701_CR353","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/pbc.24521","volume":"61","author":"F Millot","year":"2014","unstructured":"Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr Blood Cancer. 2014;61:355\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"2701_CR354","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/bjh.19535","volume":"205","author":"H Pichler","year":"2024","unstructured":"Pichler H, Sedlacek P, Meisel R, et al. Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: a prospective multicentre trial of the I-BFM Study Group. Br J Haematol. 2024;205:268\u201379.","journal-title":"Br J Haematol"},{"key":"2701_CR355","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1182\/blood-2013-03-491589","volume":"122","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, Crotta A, Ruggeri A, Eapen M, Wagner JE, Macmillan ML, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood. 2013;122:2135\u201341.","journal-title":"Blood"},{"key":"2701_CR356","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/leu.2010.285","volume":"25","author":"AB Madureira","year":"2011","unstructured":"Madureira AB, Eapen M, Locatelli F, Teira P, Zhang MJ, Davies SM, et al. Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Leukemia. 2011;25:449\u201354.","journal-title":"Leukemia"},{"key":"2701_CR357","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/leu.2010.297","volume":"25","author":"B Strahm","year":"2011","unstructured":"Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25:455\u201362.","journal-title":"Leukemia"},{"key":"2701_CR358","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol. 2009;27:3363\u20139.","journal-title":"J Clin Oncol"},{"key":"2701_CR359","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","volume":"16","author":"TG Gross","year":"2010","unstructured":"Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transpl. 2010;16:223\u201330.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR360","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","volume":"133","author":"W Woessmann","year":"2006","unstructured":"Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133:176\u201382.","journal-title":"Br J Haematol"},{"key":"2701_CR361","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","volume":"126","author":"KM Kelly","year":"2015","unstructured":"Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood. 2015;126:2452\u20138.","journal-title":"Blood"},{"key":"2701_CR362","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27033","volume":"65","author":"JM Kahn","year":"2018","unstructured":"Kahn JM, Kelly KM. Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care. Pediatr Blood Cancer. 2018;65:e27033.","journal-title":"Pediatr Blood Cancer"},{"key":"2701_CR363","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1038\/bmt.2008.69","volume":"41","author":"R Ladenstein","year":"2008","unstructured":"Ladenstein R, Potschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transpl. 2008;41:S118\u2013127.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR364","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","volume":"27","author":"KK Matthay","year":"2009","unstructured":"Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children\u2019s Oncology Group study. J Clin Oncol. 2009;27:1007\u201313.","journal-title":"J Clin Oncol"},{"key":"2701_CR365","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388:1284\u201395. de abril de","journal-title":"N Engl J Med"},{"key":"2701_CR366","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2014.105569","volume":"99","author":"S Samarasinghe","year":"2014","unstructured":"Samarasinghe S, Marsh J, Dufour C. Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next? Haematologica. 2014;99:597\u20139.","journal-title":"Haematologica"},{"key":"2701_CR367","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/bjh.13614","volume":"171","author":"C Dufour","year":"2015","unstructured":"Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171:585\u201394.","journal-title":"Br J Haematol"},{"key":"2701_CR368","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/bmt.2017.40","volume":"52","author":"J Burman","year":"2017","unstructured":"Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, et al. Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2017;52:1133\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR369","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","volume":"141","author":"F Barzaghi","year":"2018","unstructured":"Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol. 2018;141:1036\u201349.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"2701_CR370","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3324\/haematol.2015.138727","volume":"101","author":"R Devillier","year":"2016","unstructured":"Devillier R, Dalle JH, Kulasekararaj A, D\u2019aveni M, Cl\u00e9ment L, Chybicka A, et al. Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. Haematologica. 2016;101:884\u201390.","journal-title":"Haematologica"},{"key":"2701_CR371","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.bmt.1701993","volume":"24","author":"C Medeiros","year":"1999","unstructured":"Medeiros C, Zaris-Neto J, Pasquini R. Bone marrow transplantation for patients with Fanconi anaemia: reduced doses of cyclophosphamide without irradiation as conditioning. Bone Marrow Transpl. 1999;24:849\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR372","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2013-01-479733","volume":"122","author":"RP De Latour","year":"2013","unstructured":"De Latour RP, Porcher R, Dalle J-H, Aljurf M, Korthof ET, Svahn J, et al. Allogeneic haemopoietic stem cell transplantation in Fanconi anaemia: the European Group for Blood and Bone Marrow Transplantation experience. Blood. 2013;122:4279\u201386.","journal-title":"Blood"},{"key":"2701_CR373","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood-2016-09-743112","volume":"129","author":"PA Mehta","year":"2017","unstructured":"Mehta PA, Davies SM, Leemhuis T, Myers K, Kernan NA, Prockop SE, et al. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017;129:2308\u201315.","journal-title":"Blood"},{"key":"2701_CR374","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/hematology.2022000393","volume":"2022","author":"C Dufour","year":"2022","unstructured":"Dufour C, Pierri F. Modern management of Fanconi anemia. Hematology. 2022;2022:649\u201357. de diciembre de","journal-title":"Hematology"},{"key":"2701_CR375","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjh.15495","volume":"183","author":"F Fioredda","year":"2018","unstructured":"Fioredda F, Iacobelli S, Korthof ET, Knol C, van Biezen A, Bresters D, et al. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol. 2018;183:110\u20138.","journal-title":"Br J Haematol"},{"key":"2701_CR376","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.bbmt.2013.05.021","volume":"19","author":"SM Gadalla","year":"2013","unstructured":"Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. l Biol Blood Marrow Transpl. 2013;19:1238\u201343.","journal-title":"l Biol Blood Marrow Transpl"},{"key":"2701_CR377","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/bmt.2013.35","volume":"48","author":"M Ayas","year":"2013","unstructured":"Ayas M, Nassar A, Hamidieh AA, Kharfan-Dabaja M, Othman TB, Elhaddad A, et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transpl. 2013;48:1168\u201372.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR378","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bjh.12787","volume":"165","author":"F Fagioli","year":"2014","unstructured":"Fagioli F, Quarello P, Zecca M, Lanino E, Corti P, Favre C, et al. Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. Br J Haematol. 2014;165:673\u201381.","journal-title":"Br J Haematol"},{"key":"2701_CR379","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjh.18176","volume":"198","author":"FR Achini-Gutzwiller","year":"2022","unstructured":"Achini-Gutzwiller FR, Snowden JA, Corbacioglu S, Greco R. Haematopoietic stem cell transplantation for severe autoimmune diseases in children: a review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2022;198:24\u201345.","journal-title":"Br J Haematol"},{"key":"2701_CR380","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbmt.2012.12.008","volume":"19","author":"M Rabusin","year":"2013","unstructured":"Rabusin M, Snowden JA, Veys P, Quartier P, Dalle JH, Dhooge C, et al. Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children. Biol Blood Marrow Transpl. 2013;19:666\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR381","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","volume":"2","author":"JMF Silva","year":"2018","unstructured":"Silva JMF, Ladomenou F, Carpenter B, Chandra S, Sedlacek P, Formankova R, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018;2:777\u201386.","journal-title":"Blood Adv"},{"key":"2701_CR382","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","volume":"42","author":"SG Tangye","year":"2022","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42:1473\u2013507. octubre de","journal-title":"J Clin Immunol"},{"key":"2701_CR383","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","volume":"56","author":"AC Lankester","year":"2021","unstructured":"Lankester AC, Albert MH, Booth C, Gennery AR, G\u00fcng\u00f6r T, H\u00f6nig M, et al. EBMT\/ ESID inborn errors working party guidelines for hematopoietic stem cell trans- plantation for inborn errors of immunity. Bone Marrow Transpl. 2021;56:2052\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR384","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2022017667","volume":"141","author":"C Schuetz","year":"2023","unstructured":"Schuetz C, Gerke J, Ege M, Walter J, Kusters M, Worth A, et al. Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT. Blood. 2023;141:713\u201324. de febrero de","journal-title":"Blood"},{"key":"2701_CR385","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood.2022015506","volume":"140","author":"MH Albert","year":"2022","unstructured":"Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. 2022;140:1635\u201349. de octubre de","journal-title":"Blood"},{"key":"2701_CR386","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood.2024024038","volume":"144","author":"SH Lum","year":"2024","unstructured":"Lum SH, Albert MH, Gilbert P, Sirait T, Algeri M, Muratori R, et al. Outcomes of HLA-mismatched HSCT with TCR\u03b1\u03b2\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Blood. 2024;144:565\u201380. de agosto de","journal-title":"Blood"},{"key":"2701_CR387","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fped.2019.00516","volume":"7","author":"SH Lum","year":"2019","unstructured":"Lum SH, Neven B, Slatter MA, Gennery AR. Hematopoietic cell transplantation for MHC Class II deficiency. Front Pediatr. 2019;7:516.","journal-title":"Front Pediatr"},{"key":"2701_CR388","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jaip.2018.10.035","volume":"7","author":"SE Aydin","year":"2019","unstructured":"Aydin SE, Freeman AF, Al-Herz W, Al-Mousa HA, Arnaout RK, Aydin RC, et al. Hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency. J Allergy Clin Immunol Pr. 2019;7:848\u201355.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2701_CR389","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","volume":"143","author":"F Ferrua","year":"2019","unstructured":"Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol. 2019;143:2238\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"2701_CR390","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","volume":"141","author":"RM Shah","year":"2018","unstructured":"Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa T, et al. T-cell receptor \u03b1\u03b2 + and CD19 + cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141:1417\u201326.e1.","journal-title":"J Allergy Clin Immunol"},{"key":"2701_CR391","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","volume":"124","author":"A Bertaina","year":"2014","unstructured":"Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA- haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders. Blood. 2014;124:822\u20136.","journal-title":"Blood"},{"key":"2701_CR392","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood.2019001757","volume":"134","author":"A Laberko","year":"2019","unstructured":"Laberko A, Sultanova E, Gutovskaya E, Shipitsina I, Shelikhova L, Kurnikova E, et al. Mismatched related vs matched unrelated donors in TCR\u03b1\u03b2\/CD19-depleted HSCT for primary immunodeficiencies. Blood. 2019;134:1755\u201363.","journal-title":"Blood"},{"key":"2701_CR393","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","volume":"25","author":"B Neven","year":"2019","unstructured":"Neven B, Diana JS, Castelle M, Magnani A, Rosain J, Touzot F, et al. Haploi- dentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transpl. 2019;25:1363\u201373.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR394","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.bbmt.2020.07.003","volume":"26","author":"J Folloni Fernandes","year":"2020","unstructured":"Folloni Fernandes J, Nichele S, Arcuri LA, Ribeiro L, Zamperlini-Netto G, et al. Outcomes after haploidentical stem cell transplantation with post-transplantation cyclophosphamide in patients with primary immunodeficiency diseases. Biol Blood Marrow Transpl. 2020;26:1923\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2701_CR395","doi-asserted-by":"crossref","unstructured":"Merli P, Jodele S, Cook E, Myers KC, Lane A, Ryh\u00e4nen S, et al. Emapalumab for the treatment of immune-mediated graft failure after HSCT. Bone Marrow Transplant. 2024;","DOI":"10.1038\/s41409-024-02487-w"},{"key":"2701_CR396","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2024.08.020","volume":"154","author":"C Tsilifis","year":"2024","unstructured":"Tsilifis C, Speckmann C, Lum SH, Fox TA, Soler AM, Mozo Y, et al. Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: a European Society for Blood and Marrow Transplantation Inborn Errors Working Party study. J Allergy Clin Immunol. 2024;154:1534\u201344. diciembre de","journal-title":"J Allergy Clin Immunol"},{"key":"2701_CR397","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","volume":"153","author":"M Fischer","year":"2024","unstructured":"Fischer M, Olbrich P, Hadjadj J, Aumann V, Bakhtiar S, Barlogis V, et al. JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: An ESID\/EBMT-IEWP retrospective study. J Allergy Clin Immunol. 2024;153:275\u2013286.e18. enero de","journal-title":"J Allergy Clin Immunol"},{"key":"2701_CR398","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fped.2019.00435","volume":"7","author":"K Lehmberg","year":"2019","unstructured":"Lehmberg K, Moshous D, Booth C. Haematopoietic stem cell transplantation for primary haemophagocytic lymphohistiocytosis. Front Pediatr. 2019;7:435.","journal-title":"Front Pediatr"},{"key":"2701_CR399","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood-2018-01-827485","volume":"132","author":"G Lucchini","year":"2018","unstructured":"Lucchini G, Marsh R, Gilmour K, Worth A, Nademi Z, Rao A, et al. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohis-tiocytosis. Blood. 2018;132:2088\u201396.","journal-title":"Blood"},{"key":"2701_CR400","first-page":"262","volume":"5","author":"S Bakhtiar","year":"2021","unstructured":"Bakhtiar S, Salzmann-Manrique E, Blok HJ, Eikema DJ, Hazelaar S, Ayas M, et al. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. Blood Adv. 2021;5:262\u201373.","journal-title":"Blood Adv"},{"key":"2701_CR401","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","volume":"136","author":"R Chiesa","year":"2020","unstructured":"Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, et al. Despina Moshous hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136:1201\u201311.","journal-title":"Blood"},{"key":"2701_CR402","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41591-023-02789-4","volume":"30","author":"M Migliavacca","year":"2024","unstructured":"Migliavacca M, Barzaghi F, Fossati C, Rancoita PMV, Gabaldo M, Dionisio F, et al. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nat Med 2024;30:488\u201397. febrero de","journal-title":"Nat Med"},{"key":"2701_CR403","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","volume":"384","author":"DB Kohn","year":"2021","unstructured":"Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, Trevisan V, et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N Engl J Med. 2021;384:2002\u201313.","journal-title":"N Engl J Med"},{"key":"2701_CR404","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","volume":"387","author":"MJ Cowan","year":"2022","unstructured":"Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, et al. Lentiviral gene therapy for artemis-deficient SCID. N Engl J Med. 2022;387:2344\u201355. de diciembre de","journal-title":"N Engl J Med"},{"key":"2701_CR405","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","volume":"26","author":"DB Kohn","year":"2020","unstructured":"Kohn DB, Booth C, Kang EM, Pai SY, Shaw KL, Santilli G, et al. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med. 2020;26:200\u20136.","journal-title":"Nat Med"},{"key":"2701_CR406","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","volume":"6","author":"F Ferrua","year":"2019","unstructured":"Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, et al. Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study. Lancet Haematol. 2019;6:e239\u2013e253.","journal-title":"Lancet Haematol"},{"key":"2701_CR407","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41591-023-02208-8","volume":"29","author":"T Fox","year":"2023","unstructured":"Fox T, Bueren J, Candotti F, Fischer A, Aiuti A, Lankester A, et al. Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat Med 2023;29:518\u20139. marzo de","journal-title":"Nat Med"},{"key":"2701_CR408","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1089\/hum.2023.127","volume":"34","author":"C Booth","year":"2023","unstructured":"Booth C, Aiuti A. Realizing the potential of gene therapies for rare and ultra-rare inherited diseases. Hum Gene Ther. 2023;34:776\u201381. septiembre de","journal-title":"Hum Gene Ther"},{"key":"2701_CR409","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fped.2019.00433","volume":"7","author":"EY Tan","year":"2019","unstructured":"Tan EY, Boelens JJ, Jones SA, Wynn RF. Hematopoietic stem cell transplantation in inborn errors of metabolism. Front Pediatr. 2019;7:433.","journal-title":"Front Pediatr"},{"key":"2701_CR410","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1097\/HS9.0000000000000953","volume":"7","author":"F Tucci","year":"2023","unstructured":"Tucci F, Consiglieri G, Cossutta M, Bernardo ME. Current and future perspective in hematopoietic stem progenitor cell-gene therapy for inborn errors of metabolism. Hemasphere. 2023;7:e953. octubre de","journal-title":"Hemasphere"},{"key":"2701_CR411","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399:372\u201383. 22 de enero de","journal-title":"Lancet"},{"key":"2701_CR412","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","volume":"385","author":"B Gentner","year":"2021","unstructured":"Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N Engl J Med. 2021;385:1929\u201340.","journal-title":"N Engl J Med"},{"key":"2701_CR413","doi-asserted-by":"publisher","first-page":"eadi8214","DOI":"10.1126\/scitranslmed.adi8214","volume":"16","author":"G Consiglieri","year":"2024","unstructured":"Consiglieri G, Tucci F, De Pellegrin M, Guerrini B, Cattoni A, Risca G, et al. Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome. Sci Transl Med. 2024;16:eadi8214. mayo de","journal-title":"Sci Transl Med"},{"key":"2701_CR414","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s10072-021-05412-x","volume":"42","author":"A Federico","year":"2021","unstructured":"Federico A, de Visser M. New disease-modifying therapies for two genetic childhood-onset neurometabolic disorders (metachromatic leucodystrophy and adrenoleucodystrophy). Neurol Sci. 2021;42:2603\u20136.","journal-title":"Neurol Sci"},{"key":"2701_CR415","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","volume":"391","author":"CN Duncan","year":"2024","unstructured":"Duncan CN, Bledsoe JR, Grzywacz B, Beckman A, Bonner M, Eichler FS, et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391:1287\u2013301. de octubre de","journal-title":"N Engl J Med"},{"key":"2701_CR416","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2013.137","volume":"9","author":"C Sobacchi","year":"2013","unstructured":"Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9:522\u201336.","journal-title":"Nat Rev Endocrinol"},{"key":"2701_CR417","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","volume":"25","author":"J De La Fuente","year":"2019","unstructured":"De La Fuente J, Dhedin N, Koyama T, Bernaudin F, Kuentz M, Karnik L, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant. 2019;25:1197\u2013209. junio de","journal-title":"Biol Blood Marrow Transplant"},{"key":"2701_CR418","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ajh.26798","volume":"98","author":"GL Forni","year":"2023","unstructured":"Forni GL, Gianesin B, Musallam KM, Longo F, Rosso R, Lisi R, et al. Overall and complication\u2010free survival in a large cohort of patients with \u03b2\u2010thalassemia major followed over 50 years. Am J Hematol 2023;98:381\u20137. marzo de","journal-title":"Am J Hematol"},{"key":"2701_CR419","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/bmt.2015.293","volume":"51","author":"D Baronciani","year":"2016","unstructured":"Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010. Bone Marrow Transpl. 2016;51:536\u201341. abril de","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR420","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbmt.2012.08.005","volume":"19","author":"C Galambrun","year":"2013","unstructured":"Galambrun C, Pondarr\u00e9 C, Bertrand Y, Loundou A, Bordigoni P, Frange P, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant. 2013;19:62\u20138. enero de","journal-title":"Biol Blood Marrow Transplant"},{"key":"2701_CR421","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41409-021-01302-0","volume":"56","author":"LVE Oostenbrink","year":"2021","unstructured":"Oostenbrink LVE, Pool ES, Jol-van Der Zijde CM, Jansen-Hoogendijk AM, Vervat C, Van Halteren AGS, et al. Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide. Bone Marrow Transpl. 2021;56:2203\u201311. septiembre de","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR422","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13893","volume":"25","author":"V Vellaichamy Swaminathan","year":"2021","unstructured":"Vellaichamy Swaminathan V, Ravichandran N, Ramanan KM, Meena SK, Varla H, Ramakrishnan B, et al. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major. Pediatr Transpl. 2021;25:e13893.","journal-title":"Pediatr Transpl"},{"key":"2701_CR423","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2020.01.002","volume":"26","author":"U Anurathapan","year":"2020","unstructured":"Anurathapan U, Hongeng S, Pakakasama S, Songdej D, Sirachainan N, Pongphitcha P, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transplant. 2020;26:1106\u201312. junio de","journal-title":"Biol Blood Marrow Transplant"},{"key":"2701_CR424","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.12082","volume":"90","author":"S Matthes\u2010Martin","year":"2013","unstructured":"Matthes\u2010Martin S, Lawitschka A, Fritsch G, Lion T, Grimm B, Breuer S, et al. Stem cell transplantation after reduced\u2010intensity conditioning for sickle cell disease. Eur J Haematol. 2013;90:308\u201312. abril de","journal-title":"Eur J Haematol"},{"key":"2701_CR425","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","volume":"6","author":"M Eapen","year":"2019","unstructured":"Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;6:e585\u201396. noviembre de","journal-title":"Lancet Haematol"},{"key":"2701_CR426","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41409-019-0550-0","volume":"54","author":"J Foell","year":"2019","unstructured":"Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, et al. Haploidentical CD3 or \u03b1\/\u03b2 T-cell-depleted HSCT in advanced-stage sickle cell disease. Bone Marrow Transpl. 2019;54:1859\u201367. noviembre de","journal-title":"Bone Marrow Transpl"},{"key":"2701_CR427","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N Engl J Med. 2024;390:1663\u201376. de mayo de","journal-title":"N Engl J Med"},{"key":"2701_CR428","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390:1649\u201362. 9 de mayo de","journal-title":"N Engl J Med"},{"key":"2701_CR429","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","volume":"404","author":"JL Kwiatkowski","year":"2024","unstructured":"Kwiatkowski JL, Walters MC, Hongeng S, Yannaki E, Kulozik AE, Kunz JB, et al. Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet. 2024;404:2175\u201386. noviembre de","journal-title":"Lancet"},{"key":"2701_CR430","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386:617\u201328. de febrero de","journal-title":"N Engl J Med"},{"key":"2701_CR431","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/stcltm\/szac007","volume":"11","author":"I Thuret","year":"2022","unstructured":"Thuret I, Ruggeri A, Angelucci E, Chabannon C. Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia. Stem Cells Transl Med. 2022;11:407\u201314. de abril de","journal-title":"Stem Cells Transl Med"},{"key":"2701_CR432","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41409-024-02290-7","volume":"59","author":"H Schoemans","year":"2024","unstructured":"Schoemans H, Burns LJ, Liptrott SJ, Murray J, Kenyon M, Barata A, et al. Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party. Bone Marrow Transpl. 2024;59:1286\u201394. septiembre de","journal-title":"Bone Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02701-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02701-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02701-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:03:11Z","timestamp":1762185791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02701-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":432,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2701"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02701-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RG discloses speaking honoraria from Biotest, Pfizer, Medac, BMS, MSD, Neovii, Kyverna and Magenta; advisory board from Pfizer. AR: declares honoraria from Gilead and Kyte. JAS declares advisory board membership for the last 36 months with Medac, Jazz, Vertex and BMS. TA received study support from Johnson & Johnson. DA delcares MSD \u2013 local PI in a clinical trial, advisory board. AB: declares Speaker bureau or advisory board: Novartis, Roche, Sanofi, Jazz, Takeda, Hikma, Biologix, Jansen, MSD, Abbvie, Pfizer and Amgen and Research support: Novartis, Roche, Takeda, Biologix, Hikma, Pfizer and Jansen. MDH: none MK advisory board Jazz, Alexion. KK: declares speaker\u2019s bureau for Novartis, medac, Pierre Fabre. ZP declares advisory board for Amgen, Novartis and Pfizer. AMR: declares payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Alexion (AstraZeneca Rare Disease), Apellis, Kira, Novartis, Omeros, Pfizer, Roche, and Sobi; and support for attending meetings and\/or travel from Novartis and Sobi. AS declares TakedaBMS\/Celgene, MSD. DPM, EA, MK, HM, BN, PP, ISO and FC declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This manuscript did not require ethical approval as it did not involve human participants, human tissue, animals, or identifiable personal data. It is based on EBMT recommendations, providing guidance on the indications for HCT and CAR-T in haematological diseases, solid tumours, and immune disorders, with reference to previously published literature, guidelines, and supporting evidence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}